Guanfacine Once-Daily Formulation for ADHD Compliance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current guanfacine formulations require multiple daily doses, which can be inconvenient and lead to missed administrations, especially in children, and do not achieve optimal pharmacokinetic profiles for effective treatment of ADHD and other indications.
Innovation Solution
Development of a once-daily oral therapeutic composition in a discrete dose form with specific size and hardness characteristics, using a combination of excipients like Eudragit L100-55, hypromellose, and atomized glyceryl behenate, to achieve linear pharmacokinetic profiles and improved bioavailability for guanfacine, allowing for effective treatment of ADHD and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple daily doses are used, then the treatment can be effective, but patient compliance deteriorates and missed administrations increase
Solution Approach 1:
The patent segments the total daily dose into multiple smaller doses administered at different times (e.g., morning, noon, evening). This segmentation allows the drug to maintain effective plasma concentrations throughout the day while reducing the burden on patients compared to a single large dose, thereby improving compliance without sacrificing treatment effectiveness.
Solution Approach 2:
The patent employs periodic administration of the drug at regular intervals (e.g., every 8-12 hours) to maintain steady plasma concentrations. This periodic action ensures continuous therapeutic effect while creating a predictable dosing schedule that is easier for patients to follow, thus improving compliance.
2Reliability
If multiple daily doses are administered, then therapeutic effect is maintained, but the complexity of the regimen increases
Solution Approach 1:
The regimen is segmented into distinct dosing times with clear instructions for each dose. This segmentation simplifies the overall regimen by breaking down the complex requirement of continuous therapy into manageable, discrete dosing events that are easier to remember and execute.
Solution Approach 2:
The patent provides preliminary guidance on dosing schedules, administration timing, and what to do if doses are missed. This preliminary action prepares patients in advance, reducing the complexity they face during actual administration and helping them maintain the regimen without confusion.
3Ease of manufacture
If conventional formulations are used, then manufacturing is straightforward, but pharmacokinetic profiles are suboptimal
Solution Approach 1:
The patent modifies key formulation parameters including the use of specific excipients (e.g., hydroxypropyl methylcellulose, polyethylene glycol), particle size distribution of the active ingredient, and ratio of excipients to achieve an optimized pharmacokinetic profile with sustained release characteristics, while maintaining compatibility with conventional manufacturing processes.
Solution Approach 2:
The formulation uses a composite matrix of multiple excipients working together - hydroxypropyl methylcellulose for sustained release, polyethylene glycol for solubility enhancement, and other adjuvants - to achieve the desired pharmacokinetic profile while remaining manufacturable using standard pharmaceutical techniques.
Data Source
Figure 1
AI summary
Therapeutic formulations of guanfacine in a once a day single dose form which have useful overall tablet sizes are disclosed.